国际泌尿系统杂志
國際泌尿繫統雜誌
국제비뇨계통잡지
INTERNATIONAL JOURNAL OF UROLOGY AND NEPHROLOGY
2012年
5期
595-597
,共3页
李良%周术奎%王顺平%王跃闽
李良%週術奎%王順平%王躍閩
리량%주술규%왕순평%왕약민
前列腺增生%钬%激光%阳萎
前列腺增生%鈥%激光%暘萎
전렬선증생%화%격광%양위
Prostatic Hyperplasia%Holmium%Lasers Importence
目的 评估他达拉非在治疗钬激光前列腺剜除术(HoLEP)后勃起功能障碍(ED)的疗效.方法 34例HoLEP术后的ED患者接受为期3个月的他达拉非治疗,治疗后随访6个月.在治疗前后及随访6个月后记录各组患者国际勃起功能指数评分简表(IIEF-5)评分及阴茎勃起硬度并进行比较研究.结果 34例ED患者中显效19例,有效10例,无效5例,总有效率85.3% (29/34).34例患者治疗前、治疗后及停药6个月后的总体IIEF-5评分分别为(9.9±4.2)分、(19.7±3.8)分和(17.3±3.9)分,IIEF-5评分在治疗前、治疗后和随访6个月后的差异均有统计学意义(P<0.05).结论 他达拉非可以作为治疗HoLEP术后ED的一线用药.
目的 評估他達拉非在治療鈥激光前列腺剜除術(HoLEP)後勃起功能障礙(ED)的療效.方法 34例HoLEP術後的ED患者接受為期3箇月的他達拉非治療,治療後隨訪6箇月.在治療前後及隨訪6箇月後記錄各組患者國際勃起功能指數評分簡錶(IIEF-5)評分及陰莖勃起硬度併進行比較研究.結果 34例ED患者中顯效19例,有效10例,無效5例,總有效率85.3% (29/34).34例患者治療前、治療後及停藥6箇月後的總體IIEF-5評分分彆為(9.9±4.2)分、(19.7±3.8)分和(17.3±3.9)分,IIEF-5評分在治療前、治療後和隨訪6箇月後的差異均有統計學意義(P<0.05).結論 他達拉非可以作為治療HoLEP術後ED的一線用藥.
목적 평고타체랍비재치료화격광전렬선완제술(HoLEP)후발기공능장애(ED)적료효.방법 34례HoLEP술후적ED환자접수위기3개월적타체랍비치료,치료후수방6개월.재치료전후급수방6개월후기록각조환자국제발기공능지수평분간표(IIEF-5)평분급음경발기경도병진행비교연구.결과 34례ED환자중현효19례,유효10례,무효5례,총유효솔85.3% (29/34).34례환자치료전、치료후급정약6개월후적총체IIEF-5평분분별위(9.9±4.2)분、(19.7±3.8)분화(17.3±3.9)분,IIEF-5평분재치료전、치료후화수방6개월후적차이균유통계학의의(P<0.05).결론 타체랍비가이작위치료HoLEP술후ED적일선용약.
Objectives To evaluate the efficacy of tadalafil in the treatment of ED after holmium laser enucleation of the prostate(HoLEP).Methods A total of 34 patients with ED after HoLEP received 3 months of tadalafil treatment and were followed up for 6 months.The IIEF-5 scores of the patients and Penile erectile hardness were compared before and after the treatment.Results 34 cases of patients with ED markedly improved in 19 cases,effective in 10 cases,invalid in 5 cases,the total effective rate reach 85.3% (29/34).34 patients before treatment,after it and withdrawal after 6 months,the general IIEF -5 rating respectively for 9.9 ± 4.2、19.7 ± 3.8 and 17.3 ± 3.9.The IIEF-5 scores were statistically significant differences among pre-treatment、post-treatment and 6 months after drug withdrawal ( P < 0.05 ).Conclusions Tadalafil can be used as a first-iine drug for the treatment of ED after HoLEP.